Literature DB >> 26137861

Angiotensin II Induces Skeletal Muscle Atrophy by Activating TFEB-Mediated MuRF1 Expression.

Philipp Du Bois1, Cristina Pablo Tortola1, Doerte Lodka1, Melanie Kny1, Franziska Schmidt1, Kunhua Song1, Sibylle Schmidt1, Rhonda Bassel-Duby1, Eric N Olson1, Jens Fielitz2.   

Abstract

RATIONALE: Skeletal muscle wasting with accompanying cachexia is a life threatening complication in congestive heart failure. The molecular mechanisms are imperfectly understood, although an activated renin-angiotensin aldosterone system has been implicated. Angiotensin (Ang) II induces skeletal muscle atrophy in part by increased muscle-enriched E3 ubiquitin ligase muscle RING-finger-1 (MuRF1) expression, which may involve protein kinase D1 (PKD1).
OBJECTIVE: To elucidate the molecular mechanism of Ang II-induced skeletal muscle wasting. METHODS AND
RESULTS: A cDNA expression screen identified the lysosomal hydrolase-coordinating transcription factor EB (TFEB) as novel regulator of the human MuRF1 promoter. TFEB played a key role in regulating Ang II-induced skeletal muscle atrophy by transcriptional control of MuRF1 via conserved E-box elements. Inhibiting TFEB with small interfering RNA prevented Ang II-induced MuRF1 expression and atrophy. The histone deacetylase-5 (HDAC5), which was directly bound to and colocalized with TFEB, inhibited TFEB-induced MuRF1 expression. The inhibition of TFEB by HDAC5 was reversed by PKD1, which was associated with HDAC5 and mediated its nuclear export. Mice lacking PKD1 in skeletal myocytes were resistant to Ang II-induced muscle wasting.
CONCLUSION: We propose that elevated Ang II serum concentrations, as occur in patients with congestive heart failure, could activate the PKD1/HDAC5/TFEB/MuRF1 pathway to induce skeletal muscle wasting.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  angiotensin II; gene expression regulation; heart failure; histone deacetylase 5; muscle RING-finger-1; protein kinase D; transcription factor EB

Mesh:

Substances:

Year:  2015        PMID: 26137861      PMCID: PMC4537692          DOI: 10.1161/CIRCRESAHA.114.305393

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  60 in total

Review 1.  Animal models of heart failure: a scientific statement from the American Heart Association.

Authors:  Steven R Houser; Kenneth B Margulies; Anne M Murphy; Francis G Spinale; Gary S Francis; Sumanth D Prabhu; Howard A Rockman; David A Kass; Jeffery D Molkentin; Mark A Sussman; Walter J Koch; Walter Koch
Journal:  Circ Res       Date:  2012-05-17       Impact factor: 17.367

Review 2.  Skeletal muscle hypertrophy and atrophy signaling pathways.

Authors:  David J Glass
Journal:  Int J Biochem Cell Biol       Date:  2005-10       Impact factor: 5.085

3.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group.

Authors:  K Swedberg; P Eneroth; J Kjekshus; L Wilhelmsen
Journal:  Circulation       Date:  1990-11       Impact factor: 29.690

4.  Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.

Authors:  R M A van de Wal; H W M Plokker; D J A Lok; F Boomsma; F A L van der Horst; D J van Veldhuisen; W H van Gilst; A A Voors
Journal:  Int J Cardiol       Date:  2006-01-26       Impact factor: 4.164

5.  IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt- and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression.

Authors:  Tadashi Yoshida; Laura Semprun-Prieto; Sergiy Sukhanov; Patrice Delafontaine
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-03-12       Impact factor: 4.733

6.  Myogenin and class II HDACs control neurogenic muscle atrophy by inducing E3 ubiquitin ligases.

Authors:  Viviana Moresi; Andrew H Williams; Eric Meadows; Jesse M Flynn; Matthew J Potthoff; John McAnally; John M Shelton; Johannes Backs; William H Klein; James A Richardson; Rhonda Bassel-Duby; Eric N Olson
Journal:  Cell       Date:  2010-10-01       Impact factor: 41.582

7.  How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?

Authors:  R J MacFadyen; A F Lee; J J Morton; S D Pringle; A D Struthers
Journal:  Heart       Date:  1999-07       Impact factor: 5.994

8.  The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis.

Authors:  Agnes Roczniak-Ferguson; Constance S Petit; Florian Froehlich; Sharon Qian; Jennifer Ky; Brittany Angarola; Tobias C Walther; Shawn M Ferguson
Journal:  Sci Signal       Date:  2012-06-12       Impact factor: 8.192

Review 9.  Pathologic consequences of increased angiotensin II activity.

Authors:  C M Ferrario; J M Flack
Journal:  Cardiovasc Drugs Ther       Date:  1996-11       Impact factor: 3.727

10.  Cooperative control of striated muscle mass and metabolism by MuRF1 and MuRF2.

Authors:  Christian C Witt; Stephanie H Witt; Stefanie Lerche; Dietmar Labeit; Walter Back; Siegfried Labeit
Journal:  EMBO J       Date:  2007-12-20       Impact factor: 11.598

View more
  39 in total

1.  Effects of ACE2 deficiency on physical performance and physiological adaptations of cardiac and skeletal muscle to exercise.

Authors:  Daisy Motta-Santos; Robson Augusto Souza Dos Santos; Marilene Oliveira; Fatimunnisa Qadri; Marko Poglitsch; Valentina Mosienko; Lenice Kappes Becker; Maria Jose Campagnole-Santos; Joseph M Penninger; Natalia Alenina; Michael Bader
Journal:  Hypertens Res       Date:  2016-04-07       Impact factor: 3.872

2.  ACE Inhibitors and Sarcopenia: Covering All the BASEs?

Authors:  Jochen Springer; Stephan von Haehling
Journal:  Drugs Aging       Date:  2016-11       Impact factor: 3.923

3.  Different effects of the deletion of angiotensin converting enzyme 2 and chronic activation of the renin-angiotensin system on muscle weakness in middle-aged mice.

Authors:  Hikari Takeshita; Koichi Yamamoto; Masaki Mogi; Satoko Nozato; Masatsugu Horiuchi; Hiromi Rakugi
Journal:  Hypertens Res       Date:  2019-12-19       Impact factor: 3.872

4.  NFκB Regulates Muscle Development and Mitochondrial Function.

Authors:  Joseph M Valentine; Mengyao E Li; Steven E Shoelson; Ning Zhang; Robert L Reddick; Nicolas Musi
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2020-03-09       Impact factor: 6.053

5.  Importance of TFEB acetylation in control of its transcriptional activity and lysosomal function in response to histone deacetylase inhibitors.

Authors:  Jianbin Zhang; Jigang Wang; Zhihong Zhou; Jung-Eun Park; Liming Wang; Shuai Wu; Xin Sun; Liqin Lu; Tianru Wang; Qingsong Lin; Siu Kwan Sze; Dongsheng Huang; Han-Ming Shen
Journal:  Autophagy       Date:  2018-07-30       Impact factor: 16.016

Review 6.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

Review 7.  The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7).

Authors:  Robson Augusto Souza Santos; Walkyria Oliveira Sampaio; Andreia C Alzamora; Daisy Motta-Santos; Natalia Alenina; Michael Bader; Maria Jose Campagnole-Santos
Journal:  Physiol Rev       Date:  2018-01-01       Impact factor: 37.312

Review 8.  Reactive Oxygen Species/Nitric Oxide Mediated Inter-Organ Communication in Skeletal Muscle Wasting Diseases.

Authors:  Lucia M Leitner; Rebecca J Wilson; Zhen Yan; Axel Gödecke
Journal:  Antioxid Redox Signal       Date:  2017-01-04       Impact factor: 8.401

Review 9.  The emerging role of aldosterone/mineralocorticoid receptors in the pathogenesis of erectile dysfunction.

Authors:  Fei Wu; Yun Lin; Qingyong Liu
Journal:  Endocrine       Date:  2018-05-02       Impact factor: 3.633

10.  Sensing Protein Quality in Cardiac Myocytes p62 Triggers a Lysosomal Response.

Authors:  Abhinav Diwan; Roberta A Gottlieb
Journal:  Circ Res       Date:  2020-07-30       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.